Faricimab Maintains Vision Improvement, Extends Intervals for RVO in Phase 3 Trials

Faricimab maintained vision improvements and extended treatment intervals up to 4 months for people with RVO in the phase 3 BALATON and COMINO trials.

Related Keywords

United States ,Levi Garraway ,Genentech ,Drug Administration ,Perchek Industries Unsplash ,Four Months ,People With Retinal Vein Occlusion ,Press Releases ,